RGH-706 / Gedeon Richter - LARVOL DELTA

The Discovery of RGH-706, a Highly Efficacious MCH1 Receptor Antagonist, for the Treatment of Obesity and Insatiable Hunger. (PubMed, J Med Chem) - "The high MCHR1 potency and excellent receptor occupancy profile of 37 translated into statistically significant body weight loss after 14 days in a DIO mice study, supporting the potential use of this compound as a weight loss agent. Compound 37 (RGH-706) has successfully completed a phase I (SAD & MAD) clinical study in the indication of obesity, followed by an exploratory Phase II study in patients with Prader-Willi Syndrome (PWS)."

Journal • Genetic Disorders • Obesity • Prader–Willi syndrome

Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome (clinicaltrials.gov) - P2 | N=39 | Completed | Sponsor: Gedeon Richter Plc. | Active, not recruiting ➔ Completed | N=176 ➔ 39

Enrollment change • Trial completion • Prader–Willi syndrome